enVVeno Medical Corporation (NVNO)
Oxford Ledge is still expanding full research coverage of NVNO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
enVVeno develops transcatheter replacement venous valves to treat severe leg venous insufficiency.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-06
- 8-K Results of operations / financial condition; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-04-29
- 10-K Annual financial report with audited statements 2026-03-26
- 8-K Results of operations / financial condition; Other material event; Financial statements and exhibits 2026-02-04
- 8-K Amendments to articles or bylaws; Financial statements and exhibits 2026-01-20
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NVNO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NVNO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.